Recurrent Implantation Failure. Female infertility of other origin
Conditions
Interventions
Intervention 1: Intervention group: Patients undergoing intradermal lymphoma therapy, In this manner, the patients spouse's blood is used to get the required PBMC, and 20,000,000 PBMC are subcutaneous
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 41 Years
Inclusion criteria
Inclusion criteria: Individuals who have had a minimum of two successive implantation failures will be included into our research. Patients without any immunotherapy in their medical records will be included in the research.
Exclusion criteria
Exclusion criteria: Patients aged below 18 years and over 41 years Patients with an aberrant Karyotype or genetic and chromosomal diseases, either personally or via their marriages Patients having coagulation disorders Patients with an underlying chronic illness requiring certain medications Patients with positive test results for HIV, HCV, or HBV Patients with a history of asthma and hypersensitivity to certain medications Patients with abnormalities within the uterus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intradermal lymphocyte therapy's impact on a healthy pregnancy in patients who have had recurrent implantation failure. Timepoint: Following a positive beta-hCG test, clinical pregnancy was assessed at 5-6 weeks. Method of measurement: Analyzing the development of the gestational sac by sonographic techniques.;Intradermal lymphocyte therapy's impact on live birth in patients who have recurrent implantation failure. Timepoint: Following a positive beta-hCG test, clinical pregnancy was assessed at 5-6 weeks. Method of measurement: Analyzing the development of the gestational sac by sonographic techniques. | — |
Secondary
| Measure | Time frame |
|---|---|
| In patients with recurrent implantation failure, the impact of intradermal lymphocyte therapy on variations in Th1, Th2, Th17, and Treg cell counts. Timepoint: Four to six weeks subsequent to the intervention. Method of measurement: Employing flow cytometry.;The impact of intradermal lymphocyte therapy on alterations in cytokine secretion from lymphocytes in individuals experiencing recurrent implantation failure. Timepoint: Four to six weeks subsequent to the intervention. Method of measurement: Employing the ELISA technique.;The impact of intradermal lymphocyte therapy on alterations in microRNAs influencing the immune system in individuals experiencing recurrent implantation failure. Timepoint: Four to six weeks subsequent to the intervention. Method of measurement: Employing the real-time PCR technique.;The impact of intradermal lymphocyte therapy on alterations in intracellular and surface molecules of immune system cells in individuals experiencing recurrent implantation failure. Timepoint: Four to six weeks subsequent to the intervention. Method of measurement: Employing flow cytometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Yousefi
Tabriz University of Medical Sciences
Outcome results
None listed